Dr. William Gradishar, MD
Medical Oncology (Medical Oncology Physician)
675 N Saint Clair St, Galter 21-100
Chicago, IL 60611
Who else practices at this address →
Cook County includes primary care (3% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb) (1982)
- Years since graduation
- 44
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 431
Licensed in Illinois since 1983, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1982Medical school: University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb)
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
IL license 036067208 (first issued 1983; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Northwestern Medicine Central Dupage Hospital Winfield, IL
- Northwestern Memorial Hospital Chicago, IL
- Northwestern Lake Forest Hospital Lake Forest, IL
- Palos Community Hospital Palos Heights, IL
- Northwestern Medicine Mchenry Mchenry, IL
Medical groups
- Northwestern Medical Faculty Foundation (4,503 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 431
- Services billed
- 87,945
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, denosumab, 1 mg | 14,640 | 45 |
| Injection, paclitaxel, 1 mg | 11,896 | 19 |
| Injection, fosaprepitant, 1 mg | 9,150 | 28 |
| Injection, pembrolizumab, 1 mg | 8,000 | 13 |
| Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg | 2,455 | 13 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,709 | 43 |
| Injection, fulvestrant, 25 mg | 1,650 | 25 |
| Injection, palonosetron hcl, 25 mcg | 1,080 | 39 |
| Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to j9395, 25 mg | 620 | 13 |
| Established patient office or other outpatient visit, 30-39 minutes | 612 | 341 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Chicago, IL | 300 |
| Tamoxifen Citrate Other prescribers in Chicago, IL | 51 |
| Ibrance (palbociclib) | 51 |
| Letrozole Other prescribers in Chicago, IL | 49 |
| Exemestane | 46 |
| Kisqali (ribociclib succinate) | 35 |
| Truqap (capivasertib) | 24 |
| Prochlorperazine Maleate Other prescribers in Chicago, IL | 16 |
| Verzenio (abemaciclib) | 16 |
| Orserdu (elacestrant hcl) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 50 payments worth $56,384 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $18,062 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $15,851 |
| Pfizer Inc. | $4,675 |
| Gilead Sciences, Inc. | $3,264 |
| F. Hoffmann-la Roche AG | $2,870 |
| Genentech, Inc. | $2,794 |
| Lilly USA, LLC | $2,250 |
| Eli Lilly and Company | $1,800 |
| Consulting Fee | $51,930 |
|---|---|
| Travel and Lodging | $2,070 |
| Food and Beverage | $1,204 |
| Speaking at a medical education program | $1,180 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| E.r. Squibb & Sons, L.l.c. Oct 2, 2025 | Consulting Fee | $14,067 |
| AstraZeneca Pharmaceuticals LP Jun 24, 2025 | Consulting Fee | $5,740 |
| AstraZeneca Pharmaceuticals LP Jun 11, 2025 | Consulting Fee | $4,920 |
| Pfizer Inc. Jun 9, 2025 | Consulting Fee TUKYSA · ONCOLOGY | $4,675 |
| F. Hoffmann-la Roche AG Jun 6, 2025 | Consulting Fee Perjeta · BioOncology | $2,870 |
| AstraZeneca Pharmaceuticals LP Feb 11, 2025 | Consulting Fee Truqap · Oncology | $2,460 |
| AstraZeneca Pharmaceuticals LP Apr 15, 2025 | Consulting Fee DATROWAY · Oncology Company’s descriptionResearch Related Service | $2,398 |
| Lilly USA, LLC Jun 24, 2025 | Consulting Fee | $2,250 |
| Gilead Sciences, Inc. Oct 23, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4253446;VEM US;10195545 | $1,820 |
| Genentech, Inc. Apr 28, 2025 | Consulting Fee Itovebi · BioOncology | $1,804 |
All 31 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Janssen Research & Development, LLC Dec 22, 2025 | Consulting Fee | $575 |
| Stemline Therapeutics Inc. Oct 31, 2025 | Consulting Fee Orserdu · Oncology | $390 |
| Gilead Sciences, Inc. Oct 23, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4253446;VEM US;10195545 | $1,820 |
| Gilead Sciences, Inc. Oct 18, 2025 | Travel and Lodging Trodelvy · ONC · travel to Foster City, CA · in-kind Company’s description;4253529;VEM US;10195545 | $634 |
| Daiichi Sankyo Inc. Oct 14, 2025 | Consulting Fee Enhertu · ONCOLOGY | $343 |
| E.r. Squibb & Sons, L.l.c. Oct 7, 2025 | Travel and Lodging travel to BOSTON, MA | $166 |
| E.r. Squibb & Sons, L.l.c. Oct 2, 2025 | Consulting Fee | $14,067 |
| Eli Lilly and Company Sep 8, 2025 | Consulting Fee VERZENIO · Oncology | $900 |
| E.r. Squibb & Sons, L.l.c. Sep 3, 2025 | Travel and Lodging travel to Boston, MA | $387 |
| E.r. Squibb & Sons, L.l.c. Sep 3, 2025 | Travel and Lodging travel to Boston, MA | $387 |
| E.r. Squibb & Sons, L.l.c. Sep 3, 2025 | Travel and Lodging travel to Boston, MA | $37.74 |
| E.r. Squibb & Sons, L.l.c. Sep 2, 2025 | Travel and Lodging travel to Boston, MA | $387 |
| AstraZeneca Pharmaceuticals LP Jul 23, 2025 | Consulting Fee ENHERTU · Oncology | $820 |
| Janssen Research & Development, LLC Jul 15, 2025 | Consulting Fee | $575 |
| AstraZeneca Pharmaceuticals LP Jun 24, 2025 | Consulting Fee | $5,740 |
| Lilly USA, LLC Jun 24, 2025 | Consulting Fee | $2,250 |
| Eli Lilly and Company Jun 18, 2025 | Consulting FeeCompany’s descriptionSERVICES TO SUPPORT RESEARCH RELATED ACTIVITIES | $900 |
| Tolmar, Inc. Jun 14, 2025 | Consulting Fee OVELIA · Endocrinology | $1,800 |
| AstraZeneca Pharmaceuticals LP Jun 11, 2025 | Consulting Fee | $4,920 |
| Pfizer Inc. Jun 9, 2025 | Consulting Fee TUKYSA · ONCOLOGY | $4,675 |
| AstraZeneca Pharmaceuticals LP Jun 9, 2025 | Travel and Lodging travel to Chicago, IL Company’s descriptionConsulting Expenses | $38.60 |
| AstraZeneca Pharmaceuticals LP Jun 9, 2025 | Travel and Lodging travel to Chicago, IL Company’s descriptionConsulting Expenses | $31.78 |
| F. Hoffmann-la Roche AG Jun 6, 2025 | Consulting Fee Perjeta · BioOncology | $2,870 |
| Stemline Therapeutics Inc. May 23, 2025 | Consulting Fee Orserdu · Oncology | $390 |
| Genentech, Inc. May 20, 2025 | Consulting Fee | $990 |
| Genentech, Inc. Apr 28, 2025 | Consulting Fee Itovebi · BioOncology | $1,804 |
| Gilead Sciences, Inc. Apr 22, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4148977;VEM US;10195545 | $730 |
| AstraZeneca Pharmaceuticals LP Apr 15, 2025 | Consulting Fee DATROWAY · Oncology Company’s descriptionResearch Related Service | $2,398 |
| Daiichi Sankyo Inc. Mar 13, 2025 | Consulting Fee Enhertu · ONCOLOGY | $514 |
| AstraZeneca Pharmaceuticals LP Feb 14, 2025 | Speaking at a medical education program | $1,180 |
| AstraZeneca Pharmaceuticals LP Feb 11, 2025 | Consulting Fee Truqap · Oncology | $2,460 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $176,141 in research payments for these studies, mostly to the institutions running them.
- Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC
Genentech, Inc. - A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT05514054
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.